Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

WEBINAR
ASOs in action: Design, screening, and personalized medicine

Date: Tuesday April 28, 2026

Time: 11:30 a.m. EST | 8:30 a.m. PST

Precision medicine is redefining what’s possible for patients with nano rare genetic diseases, and antisense oligonucleotides (ASOs) are enabling this shift through large-scale, high throughput discovery and screening. In this webinar, trusted experts from n-Lorem and Integrated DNA Technologies (IDT) explore how systematic ASO screening—rather than one off design—drives the development of highly individualized therapies that are both effective and scalable.


The discussion highlights how high throughput ASO screening, including 1-nt walking approaches, modifications, and data-driven selection are used to rapidly evaluate potency, selectivity, and mechanism across hundreds to thousands of candidates. Attendees will see how these screening datasets inform iterative ASO design decisions and feed into an end-to-end discovery workflow, from sequence selection through synthesis, testing, and optimization. The webinar also covers how access to robust ASO chemistries and industry grade synthesis speed and scale enables rapid iteration and personalization for nano-rare disease programs.

What you’ll learn

  • Why high throughput ASO screening is essential for developing effective therapies for nano-rare diseases
  • How n-Lorem uses large-scale, data driven screening to design and optimize individualized ASO treatments
  • Strategies for improving potency and selectivity during ASO optimization
  • How scalable ASO synthesis, chemistry options, and design best practices support rapid, high throughput, discovery screening and iteration


Fill out the form below to register

Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

Presenters

Kim Lennox, MSc
Kim Lennox, MSc

Principle Scientist,
Integrated DNA Technologies

Kim is a Principal Scientist in the Molecular Genetics R&D group at Integrated DNA Technologies (IDT) in Coralville, Iowa. She earned her bachelor’s degree in Genetics from Iowa State University before continuing her training in the UK as a graduate student in Biomolecular Archaeology at the University of Sheffield. Kim has spent more than two decades at IDT, where her work focuses on developing and optimizing strategies to modulate RNA expression using a broad range of chemically modified oligonucleotides. Her research spans multiple RNA modalities, including mRNAs, miRNAs, lncRNAs, circRNAs, and other noncoding RNAs. She is the author or coauthor of 27 scientific publications related to antisense technology, RNA interference, and chemical modifications for nucleic acid therapeutics.

Anthony Vu, PhD
Anthony Vu, PhD

Assistant Director of ASO Strategy Research,
n-Lorem

Dr. Anthony Vu leads efforts at n-Lorem to develop novel ASOs strategies aimed at correcting gene haploinsufficiency in ultra-rare diseases. His work focuses on building scalable platforms to identify and optimize ASOs that upregulate gene expression by targeting regulatory RNA elements, with the goal of restoring functional protein levels. He also plays a central role in advancing computation and automation tools for ASO discovery. Anthony received his Ph.D. in Biomedical Sciences from University of California, San Diego, where he investigated RNA metabolism and stress granule biology in neurodegeneration. As an NSF Graduate Research Fellow and ARCS Scholar, he brings a strong foundation in RNA biology, neurodegeneration, and bioinformatics to drive innovation in rare disease therapeutics.